Sarepta Therapeutics, Inc. (SRPT) Earns Buy Rating from Oppenheimer Holdings, Inc.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT)‘s stock had its “buy” rating restated by stock analysts at Oppenheimer Holdings, Inc. in a research note issued on Monday.
Other research analysts have also issued reports about the stock. SunTrust Banks, Inc. restated a “buy” rating on shares of Sarepta Therapeutics in a research report on Thursday, July 20th. Credit Suisse Group set a $64.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Leerink Swann restated a “buy” rating and set a $60.00 target price (up from $52.00) on shares of Sarepta Therapeutics in a research report on Tuesday, July 18th. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Finally, Royal Bank Of Canada restated a “buy” rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, June 22nd. Ten analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $62.42.
Sarepta Therapeutics (NASDAQ SRPT) traded down 2.68% on Monday, reaching $43.96. 1,459,670 shares of the company’s stock were exchanged. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $63.73. The firm has a 50 day moving average of $40.10 and a 200-day moving average of $34.92. The company’s market cap is $2.83 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to analyst estimates of $22.52 million. During the same quarter in the previous year, the company posted ($1.19) earnings per share. The company’s quarterly revenue was up 350000.0% compared to the same quarter last year. Equities analysts expect that Sarepta Therapeutics will post ($1.23) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Sarepta Therapeutics, Inc. (SRPT) Earns Buy Rating from Oppenheimer Holdings, Inc.” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/25/sarepta-therapeutics-inc-srpt-earns-buy-rating-from-oppenheimer-holdings-inc.html.
In other Sarepta Therapeutics news, SVP Alexander Cumbo sold 5,918 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $242,638.00. Following the transaction, the senior vice president now owns 22,793 shares of the company’s stock, valued at $934,513. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Douglas S. Ingram purchased 47,058 shares of the business’s stock in a transaction on Thursday, July 27th. The shares were bought at an average cost of $42.50 per share, for a total transaction of $1,999,965.00. Following the purchase, the chief executive officer now owns 382,058 shares of the company’s stock, valued at $16,237,465. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 78,056 shares of company stock worth $3,224,208. 9.60% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of SRPT. BlackRock Inc. raised its stake in Sarepta Therapeutics by 4,403.1% during the first quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock worth $156,664,000 after purchasing an additional 5,175,193 shares during the period. Camber Capital Management LLC purchased a new position in Sarepta Therapeutics during the first quarter worth approximately $39,960,000. State Street Corp raised its stake in Sarepta Therapeutics by 21.2% during the first quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock worth $94,641,000 after purchasing an additional 559,342 shares during the period. Voya Investment Management LLC raised its stake in Sarepta Therapeutics by 2,786.1% during the second quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock worth $19,165,000 after purchasing an additional 548,826 shares during the period. Finally, HealthCor Management L.P. raised its stake in Sarepta Therapeutics by 31.1% during the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after purchasing an additional 481,890 shares during the period. 65.41% of the stock is currently owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.